Preclinical Development of a Novel Therapeutic to Rejuvenate Aging Muscle Stem Cells and Enhance Muscle Strength and Function Post Hip Fracture
临床前开发一种新疗法,可以使衰老的肌肉干细胞恢复活力并增强髋部骨折后的肌肉强度和功能
基本信息
- 批准号:10768379
- 负责人:
- 金额:$ 24.74万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-09-30 至 2024-08-31
- 项目状态:已结题
- 来源:
- 关键词:AcetyltransferaseAdministrative SupplementAdultAdverse effectsAldehyde oxidaseAnimalsAwardBiological AvailabilityBloodBody WeightCanis familiarisCardiovascular systemChemicalsClinicalClinical PathologyClinical TrialsComplementDataDoseElderlyElementsEnzymesFemaleFundingFunding MechanismsGrantHalf-LifeHepatocyteHip FracturesHistologyHumanIn VitroInjuryInvestigational DrugsKilogramLiverMaximum Tolerated DoseMetabolic BiotransformationMiniature SwineMonkeysMusMuscleMuscle functionMuscle satellite cellNational Institute on AgingOralOral AdministrationOrgan WeightOutcomePharmaceutical PreparationsPharmacology StudyPhasePlasmaProcessQuality of lifeRattusRecoveryRecovery of FunctionRegimenRejuvenationResearch DesignRodentSafetySamplingSkeletal Muscle Satellite CellsSystemTestingTherapeuticTimeToxic effectToxicokineticsToxicologyU-Series Cooperative AgreementsVomitingWorkagedclinical candidatecostfood consumptionimprovedin vivoinhibitorinhibitor therapymalemanufacturemeetingsmetabolic abnormality assessmentmuscle agingmuscle strengthnovelnovel therapeuticsolder patientpharmacokinetics and pharmacodynamicsphase 1 studyphase 2 studypre-clinicalpreclinical developmentpreclinical safetyprocess optimizationscale upsmall molecule therapeuticsstem cellstherapeutic developmentvalidation studies
项目摘要
ABSTRACT
Ridgeline’s U44 direct to Phase 2 cooperative agreement award (U44AG074107) from the National Institute on
Aging has enabled rapid therapeutic development studies of RT-002, a novel oral therapeutic to promote full
functional recovery and enhance the quality-of-life in elderly adults following traumatic hip fracture. Several
critical studies were completed in Year 1 of the award which successfully earned the Year 2 funding for Ridgeline.
Particularly, the project completed in vitro cross-species (mouse, rat, dog, mini-pig, monkey, human) metabolite
identification for RT-002 using cultured hepatocytes, in vitro translational valdiations in aged human muscle-
derived progenitor cells, in vivo PK/PD studies in aged mice and rats, process optimization and scale up
synthesis of ~4 kilogram GMP-like batch of RT-002, non-GLP and GLP toxicity and safety pharmacology studies
in rats, in vivo oral dosing tolerability and toxicokinetic assessments for RT-002 in male and female dogs, and
preliminary in vivo PK/oral bioavailability and dose escalation tolerability study in male and female mini-pigs.
This supplemental project will aid in the completion of the FDA-mandated safety/toxicity studies in the chosen
mini-pig nonrodent species.
Our pivotal cross-species metabolism studies showed that our clinical candidate NNMT inhibitor drug RT-002
was metabolized similarly in rat, mini-pig, and human hepatocytes, with comparable biotransformation rates and
identical metabolites. In contrast, the turnover rates for RT-002 in mouse and monkey hepatocytes were found
to be remarkably rapid but negligable in dog hepatocytes. Importantly, the primary metabolites identified for RT-
002 in human, rat, and mini-pig hepatocytes were nearly absent in dog hepatocytes due to the absence of the
major RT-002 metabolizing enzymes, aldehyde oxidase (AO) and N-acetyltransferase (NAT) in dog liver. Taken
together it was concluded that dogs are not the appropriate nonrodent species to characterize safety and
toxicological effects of RT-002, which was further substantiated by the poor tolerability observed in dogs following
RT-002 oral dosing. Given these result, mini-pigs are chosen as the non-rodent species for the necessary RT-
002 safety/toxicology studies as proposed in this award. This supplemental project will complete the necessary
RT-002 safety/toxicology studies in male and female mini-pigs to establish the maximum tolerated dose of RT-
002 and evaluate safety and toxicity following repeated oral dosing of the drug. Outcomes from this de-risking
study will further validate mini-pigs as an ideal choice of nonrodent species for continued regulated GLP
toxicology studies and enable Ridgeline to continue developing the novel NNMT inhibitor clinical candidate RT-
002 to reach the IND-filing milestone by the end of this project period.
摘要
Ridgeline的U44直接进入第二阶段合作协议奖(U44 AG 074107),来自国家研究所,
衰老使得RT-002的快速治疗开发研究成为可能,RT-002是一种新型口服治疗剂,
功能恢复和提高老年人创伤性髋部骨折后的生活质量。几
关键的研究是在第一年完成的奖项,成功地赢得了第二年的资金山脊线。
特别是,本项目完成了体外跨物种(小鼠、大鼠、犬、小型猪、猴、人)代谢产物的研究
使用培养的肝细胞鉴定RT-002,在老年人肌肉中进行体外翻译验证-
衍生祖细胞,老年小鼠和大鼠体内PK/PD研究,工艺优化和规模扩大
RT-002 ~4千克GMP样批次合成、非GLP和GLP毒性和安全药理学研究
大鼠中,雄性和雌性犬中RT-002的体内经口给药耐受性和毒代动力学评估,以及
在雄性和雌性小型猪中进行的初步体内PK/口服生物利用度和剂量递增耐受性研究。
该补充项目将有助于完成FDA规定的所选药物的安全性/毒性研究。
小型猪非啮齿类动物。
我们的关键跨物种代谢研究表明,我们的临床候选NNMT抑制剂药物RT-002
在大鼠、小型猪和人肝细胞中代谢相似,生物转化率相当,
相同的代谢物相比之下,发现RT-002在小鼠和猴肝细胞中的转换率
在狗的肝细胞中非常迅速但可复制。重要的是,RT-1的初级代谢产物
002在人、大鼠和小型猪肝细胞中几乎不存在于狗肝细胞中,这是由于缺乏
RT-002在狗肝脏中的主要代谢酶,醛氧化酶(AO)和N-乙酰转移酶(NAT)。采取
总之,得出结论,犬不是表征安全性的适当非啮齿动物种属,
RT-002的毒理学作用,这进一步通过在犬中观察到的不良耐受性得到证实,
RT-002口服给药。鉴于这些结果,选择小型猪作为非啮齿类动物种属进行必要的RT-
002安全性/毒理学研究,如本奖项中提出的。该补充项目将完成必要的
在雄性和雌性小型猪中进行RT-002安全性/毒理学研究,以确定RT-002的最大耐受剂量
002,并评价重复口服给药后的安全性和毒性。降低风险的结果
本研究将进一步验证小型猪作为非啮齿类动物种属的理想选择,以继续进行GLP监管
毒理学研究,使Ridgeline能够继续开发新型NNMT抑制剂临床候选RT-
002在本项目期结束时达到IND申报里程碑。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Harshini Neelakantan其他文献
Harshini Neelakantan的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Harshini Neelakantan', 18)}}的其他基金
A Novel Small Molecule Oral Therapeutic to Prevent and Reverse Skeletal Muscle Atrophy in Aging Adults
一种预防和逆转老年人骨骼肌萎缩的新型小分子口服疗法
- 批准号:
10761425 - 财政年份:2023
- 资助金额:
$ 24.74万 - 项目类别:
Preclinical Development of a Novel Therapeutic to Rejuvenate Aging Muscle Stem Cells and Enhance Muscle Strength and Function Post Hip Fracture
临床前开发一种新疗法,可以使衰老的肌肉干细胞恢复活力并增强髋部骨折后的肌肉强度和功能
- 批准号:
10696182 - 财政年份:2021
- 资助金额:
$ 24.74万 - 项目类别:
Preclinical Development of a Novel Therapeutic to Rejuvenate Aging Muscle Stem Cells and Enhance Muscle Strength and Function Post Hip Fracture
临床前开发一种新疗法,可以使衰老的肌肉干细胞恢复活力并增强髋部骨折后的肌肉强度和功能
- 批准号:
10300921 - 财政年份:2021
- 资助金额:
$ 24.74万 - 项目类别:
Preclinical Development of a Novel Therapeutic to Rejuvenate Aging Muscle Stem Cells and Enhance Muscle Strength and Function Post Hip Fracture
临床前开发一种新疗法,可以使衰老的肌肉干细胞恢复活力并增强髋部骨折后的肌肉强度和功能
- 批准号:
10491300 - 财政年份:2021
- 资助金额:
$ 24.74万 - 项目类别:
Preclinical studies to validate the efficacy of novel mechanism-of-action small molecule inhibitors to treat Duchenne muscular dystrophy
验证新型作用机制小分子抑制剂治疗杜氏肌营养不良症疗效的临床前研究
- 批准号:
9908406 - 财政年份:2019
- 资助金额:
$ 24.74万 - 项目类别:
相似海外基金
A Longitudinal Qualitative Study of Fentanyl-Stimulant Polysubstance Use Among People Experiencing Homelessness (Administrative supplement)
无家可归者使用芬太尼兴奋剂多物质的纵向定性研究(行政补充)
- 批准号:
10841820 - 财政年份:2023
- 资助金额:
$ 24.74万 - 项目类别:
Proton-secreting epithelial cells as key modulators of epididymal mucosal immunity - Administrative Supplement
质子分泌上皮细胞作为附睾粘膜免疫的关键调节剂 - 行政补充
- 批准号:
10833895 - 财政年份:2023
- 资助金额:
$ 24.74万 - 项目类别:
Administrative Supplement: Life-Space and Activity Digital Markers for Detection of Cognitive Decline in Community-Dwelling Older Adults: The RAMS Study
行政补充:用于检测社区老年人认知衰退的生活空间和活动数字标记:RAMS 研究
- 批准号:
10844667 - 财政年份:2023
- 资助金额:
$ 24.74万 - 项目类别:
StrokeNet Administrative Supplement for the Funding Extension
StrokeNet 资助延期行政补充文件
- 批准号:
10850135 - 财政年份:2023
- 资助金额:
$ 24.74万 - 项目类别:
2023 NINDS Landis Mentorship Award - Administrative Supplement to NS121106 Control of Axon Initial Segment in Epilepsy
2023 年 NINDS 兰迪斯指导奖 - NS121106 癫痫轴突初始段控制的行政补充
- 批准号:
10896844 - 财政年份:2023
- 资助金额:
$ 24.74万 - 项目类别:
Biomarkers of Disease in Alcoholic Hepatitis Administrative Supplement
酒精性肝炎行政补充剂中疾病的生物标志物
- 批准号:
10840220 - 财政年份:2023
- 资助金额:
$ 24.74万 - 项目类别:
Administrative Supplement: Improving Inference of Genetic Architecture and Selection with African Genomes
行政补充:利用非洲基因组改进遗传结构的推断和选择
- 批准号:
10891050 - 财政年份:2023
- 资助金额:
$ 24.74万 - 项目类别:
Power-Up Study Administrative Supplement to Promote Diversity
促进多元化的 Power-Up 研究行政补充
- 批准号:
10711717 - 财政年份:2023
- 资助金额:
$ 24.74万 - 项目类别:
Administrative Supplement for Peer-Delivered and Technology-Assisted Integrated Illness Management and Recovery
同行交付和技术辅助的综合疾病管理和康复的行政补充
- 批准号:
10811292 - 财政年份:2023
- 资助金额:
$ 24.74万 - 项目类别:
Administrative Supplement: Genome Resources for Model Amphibians
行政补充:模型两栖动物基因组资源
- 批准号:
10806365 - 财政年份:2023
- 资助金额:
$ 24.74万 - 项目类别: